Jonathan Leventhal, MD

• Amer Zeidan
• Barbara Burtness
• Christine Ko
• Christopher Bunick
• David J Leffell
• Harriet Kluger
• Ian Odell
• Jennifer McNiff
• Joseph Paul Eder
• Keith Choate
• Kelly Olino
• Lucia Jilaveanu
• Marcus Bosenberg
• Mario Sznol
• Mary Tomayko
• Matthew Vesely
• Michael Girardi
• Nikhil Joshi
• Nikolai Podoltsev
• Peggy Myung
• Scott Gettinger
• Shari Damast
• Shawn Cowper
• William Damsky

Drug Eruptions; Dermatology; Melanoma

• 44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevusMirza F, Yumeen S, Mirza H, Zogg C, Leventhal J, Cohen J. 44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevus. Journal Of The American Academy Of Dermatology 2023, 89: ab208. DOI: 10.1016/j.jaad.2023.07.835.
• Persistent oral ulcers in a woman with thymomaLockwood N, Bhullar S, Panse G, Leventhal J. Persistent oral ulcers in a woman with thymoma. JAAD Case Reports 2023, 41: 40-43. PMID: 37842161, PMCID: PMC10568229, DOI: 10.1016/j.jdcr.2023.08.015.
• PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigensDamo M, Hornick N, Venkat A, William I, Clulo K, Venkatesan S, He J, Fagerberg E, Loza J, Kwok D, Tal A, Buck J, Cui C, Singh J, Damsky W, Leventhal J, Krishnaswamy S, Joshi N. PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature 2023, 619: 151-159. PMID: 37344588, DOI: 10.1038/s41586-023-06217-y.
• Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program databaseYumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.
• Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatmentShipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.
• Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.
• Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approachDeutsch A, Rodriguez N, Roy S, Leventhal J. Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach. JAAD Case Reports 2023, 34: 70-73. PMID: 37013105, PMCID: PMC10066506, DOI: 10.1016/j.jdcr.2023.02.010.
• Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancerAhmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.
• A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemiaChoi R, Bhullar S, McNiff J, Persico J, Leventhal J. A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia. International Journal Of Women's Dermatology 2023, 9: e069. PMID: 36846188, PMCID: PMC9949812, DOI: 10.1097/jw9.0000000000000069.
• Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerabilityBelzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.
• Factors associated with the use of adjuvant radiation therapy in stage III melanomaKing A, Lee V, Yu B, Mirza F, Zogg C, Yang D, Tran T, Leventhal J, An Y. Factors associated with the use of adjuvant radiation therapy in stage III melanoma. Frontiers In Oncology 2023, 13: 1005930. PMID: 36816935, PMCID: PMC9929351, DOI: 10.3389/fonc.2023.1005930.
• Histopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanomaBelzer A, Becerra C, Clune J, Malik M, Leventhal J, Cowper S, Johnson R. Histopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma. Journal Of Cutaneous Pathology 2023, 50: 471-474. PMID: 36645720, DOI: 10.1111/cup.14376.
• The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapyBelzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.
• Spectrum of Dermatologic Adverse Events Associated With Amivantamab UseBelzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.
• The spectrum of cutaneous immune-related adverse events in patients with skin of colorBelzer A, Mortlock R, Olamiju B, Olino K, Cohen J, Leventhal J. The spectrum of cutaneous immune-related adverse events in patients with skin of color. Journal Of The American Academy Of Dermatology 2022, 88: 1156-1158. PMID: 36470309, PMCID: PMC10838520, DOI: 10.1016/j.jaad.2022.11.051.
• Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expressionAhmad M, Murphy M, Damsky W, Leventhal J. Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. International Journal Of Dermatology 2022, 62: e424-e426. PMID: 36468831, DOI: 10.1111/ijd.16538.
• Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi surveyWilson BN, Shah R, Menzer C, Aleisa A, Sun MD, Kwong BY, Kaffenberger BH, Seminario‐Vidal L, Barker CA, Stubblefield MD, Romesser PB, Fabbrocini G, Alam M, Abdulla F, Dulmage B, Sibaud V, Anadkat M, Mazer J, Parikh D, McLellan B, Cartier H, Pugliese S, Wolkerstorfer A, Laubach H, LeBoeuf N, Leventhal J, Wan DC, Choi J, Tran T, Anderson RR, Markova A, Rossi A. Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey. British Journal Of Dermatology 2022, 187: 1054-1056. PMID: 36047980, PMCID: PMC10087782, DOI: 10.1111/bjd.21852.
• Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)Belzer A, Silber A, Mehra S, Gilani S, Leventhal JS. Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1). British Journal Of Dermatology 2022, 187: e168-e168. PMID: 35633104, DOI: 10.1111/bjd.21654.
• Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case seriesAhearn EL, Belzer A, Cohen SR, Leventhal JS, Deverapalli SC. Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series. International Journal Of Dermatology 2022, 62: e411-e414. PMID: 36271737, DOI: 10.1111/ijd.16464.
• Treatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquineChoi R, Bhullar S, Glusac E, Podoltsev N, Leventhal J. Treatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquine. International Journal Of Dermatology 2022, 62: e398-e399. PMID: 36214463, DOI: 10.1111/ijd.16441.
• 34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedemaBelzer A, Bosenberg M, Leventhal J. 34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedema. Journal Of The American Academy Of Dermatology 2022, 87: ab122. DOI: 10.1016/j.jaad.2022.06.521.
• Janus kinase‐signal transducers and activators of transcription (JAK–STAT) activation in anti‐programmed death‐1 (PD‐1) therapy—Associated granuloma annulare: a case seriesChoi R, Wang JX, Damsky W, Wang A, Galan A, Leventhal J. Janus kinase‐signal transducers and activators of transcription (JAK–STAT) activation in anti‐programmed death‐1 (PD‐1) therapy—Associated granuloma annulare: a case series. International Journal Of Dermatology 2022, 62: e323-e325. PMID: 35933688, PMCID: PMC9902571, DOI: 10.1111/ijd.16375.
• 003 Atypical bullous pemphigoid due to radiation therapyBelzer A, Ko C, Leventhal J. 003 Atypical bullous pemphigoid due to radiation therapy. Journal Of Investigative Dermatology 2022, 142: s1. DOI: 10.1016/j.jid.2022.05.057.
• 030 Immune checkpoint inhibitor-induced bullous pemphigoid skin has elevated interleukin-4 and interleukin-13 expression and responds to IL-4R inhibitionShipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. 030 Immune checkpoint inhibitor-induced bullous pemphigoid skin has elevated interleukin-4 and interleukin-13 expression and responds to IL-4R inhibition. Journal Of Investigative Dermatology 2022, 142: s5. DOI: 10.1016/j.jid.2022.05.084.
• 103 JAK-STAT activation in anti-PD-1 therapy-associated granuloma annulareChoi R, Wang J, Damsky W, Wang A, Galan A, Leventhal J. 103 JAK-STAT activation in anti-PD-1 therapy-associated granuloma annulare. Journal Of Investigative Dermatology 2022, 142: s18. DOI: 10.1016/j.jid.2022.05.038.
• PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient DermatologistBelzer A, Bhullar S, Leventhal J. PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports 2022, 11: 158-167. DOI: 10.1007/s13671-022-00365-6.
• Skin eruption involving bilateral breasts following radiation therapy for invasive ductal carcinoma of the left breastBelzer A, McNiff JM, Leventhal JS. Skin eruption involving bilateral breasts following radiation therapy for invasive ductal carcinoma of the left breast. International Journal Of Women's Dermatology 2022, 8: e016. PMID: 35619675, PMCID: PMC9112382, DOI: 10.1097/jw9.0000000000000016.
• Treatment of multifocal cutaneous Rosai-Dorfman disease with radiotherapyChoi R, Ring N, McNiff JM, Wilson LD, Martin K, Leventhal J. Treatment of multifocal cutaneous Rosai-Dorfman disease with radiotherapy. JAAD Case Reports 2022, 23: 106-108. PMID: 35495976, PMCID: PMC9039858, DOI: 10.1016/j.jdcr.2022.03.027.
• Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.Lacouture M, Patel A, LeBoeuf N, Marathe O, Leventhal J, Choi J, Lam E, Kaffenberger B, Voss M, Webb M, Tyler R, Ju J, Tang H, Luo J, Anadkat M, Vogelzang N. Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients. Journal Of Clinical Oncology 2022, 40: tps396-tps396. DOI: 10.1200/jco.2022.40.6_suppl.tps396.
• Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfateXie CB, Kidacki M, Ring N, Panse G, Leventhal JS. Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfate. JAAD Case Reports 2021, 17: 31-33. PMID: 34692964, PMCID: PMC8517711, DOI: 10.1016/j.jdcr.2021.09.013.
• Bullous Pemphigoid Exacerbated by Radiation Therapy: An Atypical PresentationChoi R, Cowper S, Young M, Leventhal J. Bullous Pemphigoid Exacerbated by Radiation Therapy: An Atypical Presentation. Advances In Radiation Oncology 2021, 7: 100794. PMID: 34984247, PMCID: PMC8693003, DOI: 10.1016/j.adro.2021.100794.
• LB777 Atypical presentation of Bullous Pemphigoid unmasked by radiation therapyChoi R, Young M, Cowper S, Leventhal J. LB777 Atypical presentation of Bullous Pemphigoid unmasked by radiation therapy. Journal Of Investigative Dermatology 2021, 141: b16. DOI: 10.1016/j.jid.2021.07.043.
• LB778 A quantitative scoring system for cutaneous immune-related adverse eventsHornick N, Damo M, Leventhal J, Joshi N. LB778 A quantitative scoring system for cutaneous immune-related adverse events. Journal Of Investigative Dermatology 2021, 141: b17. DOI: 10.1016/j.jid.2021.07.044.
• US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.
• Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast CancerLaird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.
• Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse eventPach J, Moody K, Ring N, Panse G, Zhang M, Deverapalli S, Leventhal J. Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event. JAAD Case Reports 2021, 13: 118-120. PMID: 34189226, PMCID: PMC8220292, DOI: 10.1016/j.jdcr.2021.05.002.
• Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic MelanomaPach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.
• Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitorsColeman EL, Olamiju B, Leventhal JS. Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors. Oncology Reports 2020, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.
• Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapySingh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, Leventhal J, Damsky W. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Reports 2020, 7: 122-124. PMID: 33426249, PMCID: PMC7777455, DOI: 10.1016/j.jdcr.2020.11.016.
• Skin puckering and edema during durvalumab therapyOlamiju B, Odell I, Panse G, Eder JP, Leventhal JS. Skin puckering and edema during durvalumab therapy. JAAD Case Reports 2020, 7: 110-112. PMID: 33364282, PMCID: PMC7750709, DOI: 10.1016/j.jdcr.2020.11.019.
• Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management GuidelinesLacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou‐Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2020, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.
• Dermatologic toxicities associated with radiation therapy in women with breast cancerRamseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.
• Association between halo nevi and melanoma in adults: A multicenter retrospective case seriesHaynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM. Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal Of The American Academy Of Dermatology 2020, 84: 1164-1166. PMID: 32822787, DOI: 10.1016/j.jaad.2020.08.056.
• LB960 Oncodermatologic conditions in skin of colorOlamiju B, Leventhal J. LB960 Oncodermatologic conditions in skin of color. Journal Of Investigative Dermatology 2020, 140: b14. DOI: 10.1016/j.jid.2020.05.056.
• 868 Pathogenesis based therapy improves cutaneous abnormalities in porokeratosis- A pilot studyAzmony L, Sun Q, Hamilton C, Lim Y, Leventhal J, Paller A, Choate K. 868 Pathogenesis based therapy improves cutaneous abnormalities in porokeratosis- A pilot study. Journal Of Investigative Dermatology 2020, 140: s113. DOI: 10.1016/j.jid.2020.03.884.
• Cutaneous immune-related adverse events to checkpoint inhibitorsMalviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.
• Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapiesOlamiju B, Bhullar S, Coleman EL, Leventhal JS. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal Of The American Academy Of Dermatology 2020, 84: 806-808. PMID: 32526318, DOI: 10.1016/j.jaad.2020.06.010.
• Late onset radiation-induced morphea of the breast: a case of an atypical presentation with response to phototherapyOlamiju B, Leventhal J. Late onset radiation-induced morphea of the breast: a case of an atypical presentation with response to phototherapy. International Journal Of Women's Dermatology 2020, 6: 231-232. DOI: 10.1016/j.ijwd.2020.03.027.
• Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical courseMirza FN, Yumeen S, Zogg CK, Mirza HN, Leventhal JS. Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course. Journal Of The American Academy Of Dermatology 2020, 83: 1827-1830. PMID: 32446830, PMCID: PMC7669598, DOI: 10.1016/j.jaad.2020.05.086.
• Tender subcubcutaneous plaques in a patient with acute myeloid leukemiaOlamiju B, Myung P, Grant M, Leventhal JS. Tender subcubcutaneous plaques in a patient with acute myeloid leukemia. International Journal Of Dermatology 2020, 60: 311-313. PMID: 32424815, DOI: 10.1111/ijd.14943.
• Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case seriesLigtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.
• A rapidly growing, exophytic nodule on the chestRamseier JY, Cowper SE, Leventhal JS, Vesely MD. A rapidly growing, exophytic nodule on the chest. JAAD Case Reports 2020, 6: 417-419. PMID: 32382633, PMCID: PMC7200183, DOI: 10.1016/j.jdcr.2020.02.038.
• Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.
• Near total body vitiligo secondary to immunotherapy for metastatic melanomaOlamiju B, Leventhal J. Near total body vitiligo secondary to immunotherapy for metastatic melanoma. British Journal Of Dermatology 2020, 183: e2-e2. PMID: 32147813, DOI: 10.1111/bjd.18944.
• Tense Bullae and Pruritus.Vesely MD, Olamiju BA, Leventhal JS. Tense Bullae and Pruritus. American Family Physician 2020, 101: 305-306. PMID: 32109022, PMCID: PMC7255498.
• Successful management of malodor from fungating tumors using crushed metronidazole tabletsHu JK, Ligtenberg KG, Leventhal J, Bunick CG. Successful management of malodor from fungating tumors using crushed metronidazole tablets. JAAD Case Reports 2019, 6: 26-29. PMID: 31909133, PMCID: PMC6938872, DOI: 10.1016/j.jdcr.2019.10.025.
• Pruritic reticulation: don't ‘fiddle’ aroundSalam A, Peleva E, Cowper SE, Leventhal JS. Pruritic reticulation: don't ‘fiddle’ around. Clinical And Experimental Dermatology 2019, 45: 501-504. PMID: 31762054, DOI: 10.1111/ced.14135.
• Dermatologic conditions in women receiving systemic cancer therapyFerreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. International Journal Of Women's Dermatology 2019, 5: 285-307. PMID: 31909148, PMCID: PMC6938835, DOI: 10.1016/j.ijwd.2019.10.003.
• The life-threatening eruptions of immune checkpoint inhibitor therapyColeman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.
• The rash in life-threatening metabolic and endocrine disordersMirza FN, Leventhal JS. The rash in life-threatening metabolic and endocrine disorders. Clinics In Dermatology 2019, 38: 79-85. PMID: 32197751, DOI: 10.1016/j.clindermatol.2019.10.018.
• Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid diseaseColeman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.
• Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapyAtzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2019, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.
• B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitorsDamsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.
• Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulareDamsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.
• 390 Second-hit, post-zygotic PMVKand MVD mutations cause linear porokeratosisAtzmony L, Khan H, Lim Y, Paller A, Levinsohn J, Holland K, Mirza F, Yin E, Ko C, Leventhal J, Choate K. 390 Second-hit, post-zygotic PMVKand MVD mutations cause linear porokeratosis. Journal Of Investigative Dermatology 2019, 139: s67. DOI: 10.1016/j.jid.2019.03.466.
• Second-Hit, Postzygotic PMVK and MVD Mutations in Linear PorokeratosisAtzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, Mirza FN, Yin E, Ko CJ, Leventhal JS, Choate KA. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatology 2019, 155: 548-555. PMID: 30942823, PMCID: PMC6506890, DOI: 10.1001/jamadermatol.2019.0016.
• Multiple Lip Papules and Nodules in an Adult ManSmith N, Glusac E, Leventhal J. Multiple Lip Papules and Nodules in an Adult Man. JAMA Dermatology 2019, 155: 485-486. PMID: 30840027, DOI: 10.1001/jamadermatol.2018.5240.
• Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapyMittal A, Mittal V, Panse G, Choi JN, Kwong BY, Leventhal JS. Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy. Journal Of The American Academy Of Dermatology 2019, 81: 260-262. PMID: 30797843, DOI: 10.1016/j.jaad.2019.02.039.
• How Clinical Immunologists Can Impact Patient Care within a Cancer Center: A Tale of 3 PatientsBelmont A, Leventhal J, Price C. How Clinical Immunologists Can Impact Patient Care within a Cancer Center: A Tale of 3 Patients. Journal Of Allergy And Clinical Immunology 2019, 143: ab232. DOI: 10.1016/j.jaci.2018.12.707.
• Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumorsColeman E, Panse G, Cowper S, Lacy J, Leventhal J. Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors. JAAD Case Reports 2019, 5: 170-172. PMID: 30740499, PMCID: PMC6357547, DOI: 10.1016/j.jdcr.2018.11.021.
• Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for managementColeman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.
• Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell CarcinomaTotonchy MB, Leventhal JS, Ko CJ, Leffell DJ. Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma. Dermatologic Surgery 2018, 44: 1466-1470. PMID: 29360655, DOI: 10.1097/dss.0000000000001465.
• Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretinColeman E, Panse G, Haldas J, Gettinger SN, Leventhal JS. Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Reports 2018, 4: 669-671. PMID: 30112450, PMCID: PMC6091308, DOI: 10.1016/j.jdcr.2018.06.022.
• Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinomaTurner N, Leventhal J. Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma. International Journal Of Dermatology 2018, 57: e90-e92. PMID: 30091457, DOI: 10.1111/ijd.14191.
• Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapySiegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.
• Necrotic cheek ulcer in a liver transplant patientColeman E, Levy L, Panse G, Leventhal JS. Necrotic cheek ulcer in a liver transplant patient. International Journal Of Dermatology 2018, 58: 285-287. PMID: 29926899, PMCID: PMC6309531, DOI: 10.1111/ijd.14101.
• Erythema Nodosum–like Eruption in the Setting of Sorafenib TherapyColeman EL, Cowper SE, Stein SM, Leventhal JS. Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy. JAMA Dermatology 2018, 154: 369-370. PMID: 29453869, DOI: 10.1001/jamadermatol.2017.5733.
• Violaceous plaques and papulonodules on the umbilicus.Leventhal JS, Yin E, Imaeda S. Violaceous plaques and papulonodules on the umbilicus. Cutis 2018, 101: e11-e13. PMID: 29718029.
• Lip ulceration in an immunocompromised patientMittal A, Leventhal JS. Lip ulceration in an immunocompromised patient. JAAD Case Reports 2018, 4: 214-216. PMID: 29527548, PMCID: PMC5842327, DOI: 10.1016/j.jdcr.2017.07.011.
• Radiation Dermatitis: Recognition, Prevention, and Management.Leventhal J, Young MR. Radiation Dermatitis: Recognition, Prevention, and Management. Oncology (Williston Park, N.Y.) 2017, 31: 885-7, 894-9. PMID: 29297172.
• Image Gallery: Juvenile autoimmune pemphigus presenting with diffuse gingival hypertrophy and antibodies against desmocollin 3Leventhal JS, Haberland CM, Cowper SE, Tomayko MM. Image Gallery: Juvenile autoimmune pemphigus presenting with diffuse gingival hypertrophy and antibodies against desmocollin 3. British Journal Of Dermatology 2017, 177: e226-e226. PMID: 29192983, DOI: 10.1111/bjd.15954.
• A 71‐year‐old man with a hemorrhagic vesicular eruptionHamilton CE, King BA, Cowper SE, Hochster H, Leventhal JS. A 71‐year‐old man with a hemorrhagic vesicular eruption. International Journal Of Dermatology 2017, 57: 147-148. PMID: 29057466, DOI: 10.1111/ijd.13793.
• Cyanosis of the foot.Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA. Cyanosis of the foot. Cutis 2017, 100: 206;209;210. PMID: 29136053.
• The skin as a window to the blood: Cutaneous manifestations of myeloid malignanciesLi AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.
• Ulcerative Plaques and Nodules on the Lower Extremity: A Quiz.Mittal A, Subtil A, Leventhal JS. Ulcerative Plaques and Nodules on the Lower Extremity: A Quiz. Acta Dermato-venereologica 2017, 97: 866-867. PMID: 28350040, DOI: 10.2340/00015555-2659.
• Purpuric lesions of the scalp, axillae, and groin of an infant.Khurana M, Leventhal JS, Levy L, McNiff JM, Antaya RJ. Purpuric lesions of the scalp, axillae, and groin of an infant. Cutis 2017, 99: 398;405;406. PMID: 28686757.
• Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumabLi AW, Ko CJ, Leventhal JS. Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab. European Journal Of Dermatology 2017, 27: 325-326. PMID: 28414193, DOI: 10.1684/ejd.2017.2989.
• Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenonMittal A, Leventhal JS. Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon. JAAD Case Reports 2017, 3: 190-195. PMID: 28443306, PMCID: PMC5394206, DOI: 10.1016/j.jdcr.2017.02.014.
• Epidemiology and Screening of Pigmented LesionsShi V, Leventhal J. Epidemiology and Screening of Pigmented Lesions. 2017 DOI: 10.1891/9781617052958.0001.
• Alternative Therapies: Topical Treatment and InjectionsTotonchy M, Leventhal J. Alternative Therapies: Topical Treatment and Injections. 2017 DOI: 10.1891/9781617052958.0013.
• Topical drug-induced subacute cutaneous lupus erythematosus isolated to the handsRamachandran SM, Leventhal JS, Franco LG, Mir A, Walters RF, Franks AG. Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands. Lupus Science & Medicine 2017, 4: e000207. PMID: 28331627, PMCID: PMC5353283, DOI: 10.1136/lupus-2017-000207.
• Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel findingYin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding. JAAD Case Reports 2017, 3: 90-92. PMID: 28280766, PMCID: PMC5334519, DOI: 10.1016/j.jdcr.2016.10.008.
• Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndromeWeed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.
• Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 ImmunotherapyShi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.
• A 54‐year‐old woman with arthritis and discoloration of the hands, ears, and scleraeYin ES, Knispel JD, McNiff JM, Leventhal JS. A 54‐year‐old woman with arthritis and discoloration of the hands, ears, and sclerae. International Journal Of Dermatology 2016, 56: 715-717. PMID: 27651033, DOI: 10.1111/ijd.13415.
• Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% creamLeventhal JS, Odell ID, Imaeda S, Maverakis E, King BA. Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream. JAAD Case Reports 2016, 2: 114-116. PMID: 27051847, PMCID: PMC4810288, DOI: 10.1016/j.jdcr.2016.01.004.
• Skin manifestations of endocrine and neuroendocrine tumorsLeventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Seminars In Oncology 2016, 43: 335-340. PMID: 27178685, DOI: 10.1053/j.seminoncol.2016.02.022.
• Recurrent Coxsackievirus Infection in a Patient with Lamellar IchthyosisDamsky WE, Leventhal JS, Khalil D, Vesely MD, Craiglow BG, Milstone LM, Choate KA. Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis. Pediatric Dermatology 2016, 33: e140-e142. PMID: 26821985, PMCID: PMC7226923, DOI: 10.1111/pde.12769.
• 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case seriesShi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-654. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.
• Purpuric Lesions on Acral SitesGibson J, Leventhal JS, King B. Purpuric Lesions on Acral Sites. JAMA Dermatology 2015, 151: 659-660. PMID: 25738282, DOI: 10.1001/jamadermatol.2014.5198.
• Postoperative pathergic pyoderma gangrenosum after aortic aneurysm repairLeventhal JS, Tlougan BE, Mandell JA, Friedman‐Kien A, Meehan SA. Postoperative pathergic pyoderma gangrenosum after aortic aneurysm repair. International Journal Of Dermatology 2013, 52: 1401-1403. PMID: 24164156, DOI: 10.1111/j.1365-4632.2011.05198.x.
• Crystal deodorant‐induced axillary granulomatous dermatitisLeventhal JS, Farhadian JA, Miller KE, Tlougan BE, Patel RR, Sanchez MR. Crystal deodorant‐induced axillary granulomatous dermatitis. International Journal Of Dermatology 2013, 53: e59-e60. PMID: 23621443, DOI: 10.1111/j.1365-4632.2012.05686.x.
• Skin Conditions of Baseball, Cricket, and Softball PlayersFarhadian JA, Tlougan BE, Adams BB, Leventhal JS, Sanchez MR. Skin Conditions of Baseball, Cricket, and Softball Players. Sports Medicine 2013, 43: 575-589. PMID: 23456491, DOI: 10.1007/s40279-013-0022-4.
• Is it time to re-evaluate the treatment of pemphigus?Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? Journal Of Drugs In Dermatology 2012, 11: 1200-6. PMID: 23134985.
• Hypersensitivity Reactions to Vaccine ConstituentsLeventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity Reactions to Vaccine Constituents. Dermatitis 2012, 23: 102-109. PMID: 22653170, DOI: 10.1097/der.0b013e31825228cf.
• Aquatic Sports Dermatoses: Clinical Presentation and Treatment GuidelinesLeventhal J, Tlougan B. Aquatic Sports Dermatoses: Clinical Presentation and Treatment Guidelines. 2012 DOI: 10.5772/26483.